Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Apr 15, 2025; 17(4): 103631
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103631
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103631
Table 6 Comparison of adverse reactions, n (%)
| Group | Control group (n = 50) | Observation group (n = 50) | χ2 | P value |
| Diarrhea | 3 (6.00) | 4 (8.00) | 0.154 | 0.695 |
| Loss of appetite | 10 (20.00) | 8 (16.00) | 0.271 | 0.603 |
| ALT elevation | 11 (22.00) | 8 (16.00) | 0.585 | 0.444 |
| Proteinuria | 3 (6.00) | 2 (4.00) | 0.211 | 0.646 |
| Hand-foot syndrome | 1(2.00) | 3 (6.00) | 1.042 | 0.307 |
- Citation: Liang LW, Luo RH, Huang ZL, Tang LN. Clinical observation of nivolumab combined with cabozantinib in the treatment of advanced hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(4): 103631
- URL: https://www.wjgnet.com/1948-5204/full/v17/i4/103631.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i4.103631